mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
- PMID: 16452206
- PMCID: PMC3193604
- DOI: 10.1158/0008-5472.CAN-05-2925
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
Abstract
Stimulation of the insulin and insulin-like growth factor I (IGF-I) receptor activates the phosphoinositide-3-kinase/Akt/mTOR pathway causing pleiotropic cellular effects including an mTOR-dependent loss in insulin receptor substrate-1 expression leading to feedback down-regulation of signaling through the pathway. In model systems, tumors exhibiting mutational activation of phosphoinositide-3-kinase/Akt kinase, a common event in cancers, are hypersensitive to mTOR inhibitors, including rapamycin. Despite the activity in model systems, in patients, mTOR inhibitors exhibit more modest antitumor activity. We now show that mTOR inhibition induces insulin receptor substrate-1 expression and abrogates feedback inhibition of the pathway, resulting in Akt activation both in cancer cell lines and in patient tumors treated with the rapamycin derivative, RAD001. IGF-I receptor inhibition prevents rapamycin-induced Akt activation and sensitizes tumor cells to inhibition of mTOR. In contrast, IGF-I reverses the antiproliferative effects of rapamycin in serum-free medium. The data suggest that feedback down-regulation of receptor tyrosine kinase signaling is a frequent event in tumor cells with constitutive mTOR activation. Reversal of this feedback loop by rapamycin may attenuate its therapeutic effects, whereas combination therapy that ablates mTOR function and prevents Akt activation may have improved antitumor activity.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3193604/bin/nihms-325457-f0001.gif)
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3193604/bin/nihms-325457-f0001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3193604/bin/nihms-325457-f0003.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3193604/bin/nihms-325457-f0004.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3193604/bin/nihms-325457-f0005.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3193604/bin/nihms-325457-f0005.gif)
Comment in
-
How Compensatory Mechanisms and Adaptive Rewiring Have Shaped Our Understanding of Therapeutic Resistance in Cancer.Cancer Res. 2021 Dec 15;81(24):6074-6077. doi: 10.1158/0008-5472.CAN-21-3605. Cancer Res. 2021. PMID: 34911779 Free PMC article.
Similar articles
-
Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.Mol Cancer Ther. 2005 Oct;4(10):1533-40. doi: 10.1158/1535-7163.MCT-05-0068. Mol Cancer Ther. 2005. PMID: 16227402
-
Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.Mol Cancer Ther. 2009 Apr;8(4):742-53. doi: 10.1158/1535-7163.MCT-08-0668. Mol Cancer Ther. 2009. PMID: 19372546 Free PMC article.
-
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.Blood. 2008 Jan 1;111(1):379-82. doi: 10.1182/blood-2007-03-080796. Epub 2007 Sep 18. Blood. 2008. PMID: 17878402
-
New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).Curr Top Microbiol Immunol. 2010;347:241-62. doi: 10.1007/82_2010_64. Curr Top Microbiol Immunol. 2010. PMID: 20549474 Review.
-
Targeting Akt/PKB in pediatric tumors: A review from preclinical to clinical trials.Pharmacol Res. 2022 Sep;183:106403. doi: 10.1016/j.phrs.2022.106403. Epub 2022 Aug 18. Pharmacol Res. 2022. PMID: 35987481 Review.
Cited by
-
Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions.Mol Cancer. 2024 Aug 10;23(1):164. doi: 10.1186/s12943-024-02072-1. Mol Cancer. 2024. PMID: 39127670 Free PMC article. Review.
-
The Role of the PI3K/Akt/mTOR Axis in Head and Neck Squamous Cell Carcinoma.Biomedicines. 2024 Jul 19;12(7):1610. doi: 10.3390/biomedicines12071610. Biomedicines. 2024. PMID: 39062182 Free PMC article. Review.
-
Assessing RNA-Seq Workflow Methodologies Using Shannon Entropy.Biology (Basel). 2024 Jun 28;13(7):482. doi: 10.3390/biology13070482. Biology (Basel). 2024. PMID: 39056677 Free PMC article.
-
Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer.Nat Commun. 2024 Jul 19;15(1):6076. doi: 10.1038/s41467-024-50063-z. Nat Commun. 2024. PMID: 39025835 Free PMC article.
-
Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models.NPJ Breast Cancer. 2024 Jun 5;10(1):40. doi: 10.1038/s41523-024-00648-0. NPJ Breast Cancer. 2024. PMID: 38839777 Free PMC article.
References
-
- Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489–501. - PubMed
-
- Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004;4:335–48. - PubMed
-
- Oldham S, Hafen E. Insulin/IGF and target of rapamycin signaling: a TOR de force in growth control. Trends Cell Biol. 2003;13:79–85. - PubMed
-
- Haruta T, Uno T, Kawahara J, et al. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol. 2000;14:783–94. - PubMed
-
- Pederson TM, Kramer DL, Rondinone CM. Serine/threonine phosphorylation of IRS-1 triggers its degradation: possible regulation by tyrosine phosphorylation. Diabetes. 2001;50:24–31. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous